Sign Out
Pregnancy: There are no adequate data from the use of pregabalin in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown.
Rewisca should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus. Effective contraception must be used in women of child bearing potential.
Breast-feeding: Pregabalin is excreted into breast milk (see Pharmacology: Pharmacokinetics under Actions). As the safety of pregabalin on newborns/infants is unknown, breast-feeding is not recommended during treatment with pregabalin. A decision must be made whether to discontinue breast feeding or to discontinue pregabalin therapy taking into account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
